Altmeyer P, Wehrenberg O, Holzmann H, Paul E, Kimmig W K, Wassilew S W, Petres J, Korger G
Zentrum für Dermatologie und Venerologie, J.W. Goethe-Universität Frankfurt/Main.
Hautarzt. 1991 Dec;42(12):759-63.
A herpes simplex type I subunit vaccine developed by Behring-Werke (Marburg/Lahn, FRG) was compared with placebo for therapeutic effectiveness in the treatment of recurrent orolabial herpes simplex in a multicentre study involving the major hospitals in Frankfurt/Main (n = 34), Hamburg (n = 18), Giessen (n = 17) und Kassel (n = 14). The effectiveness of the vaccine was judged on the reduction in the frequency of recurrences. Within the period of the 8-month study there was no statistically significant difference in the frequency of recurrences with vaccine or placebo. Both placebo and verum led to a significant decrease in the number of recurrences of orolabial herpes simplex, but the effect of placebo was slightly more pronounced.
